Ocugen Provides Business Update with Third Quarter 2026 Financial Results
A $16.562 million derivative-liability fair-value gain accompanied the narrower quarterly net loss, while operating loss increased.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocugen (NASDAQ: OCGN) reported a narrower third-quarter net loss while advancing gene therapy trials and expanding OCU400 licensing.
Net loss was $3.598 million, or $0.01 per share, versus $20.051 million, or $0.07 per share, a year earlier. Revenue rose to $1.951 million from $1.752 million. Cash, restricted cash and short-term investments totaled $84.6 million; Ocugen expects runway into 2028.
The Roots Pharmaceutical MENA license provides eligibility for up to $4 million in combined upfront fees and potential initial development milestones, up to $255 million in potential sales milestones and a 22% net-sales royalty. OCU400 received provisional Bahamas approval, with final approval pending and potential enrollment as early as year-end. Ocugen expects OCU400 Phase 3 data in Q1 2027 and OCU410ST pivotal data in Q2 2027, with license applications planned afterward. OCU410 Phase 3 dosing began.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.OCU400 MENA license includes up to $255 million in potential sales milestones and a 22% net-sales royalty. 1× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Liquidity totaled $84.6 million at September 30, 2026; Ocugen expects cash runway into 2028.
- Moderate pointQ3 net loss narrowed to $3.598 million, or $0.01 per share, from $20.051 million, or $0.07.
- Minor point. Forward-looking: it has not happened yet and may not happen.OCU400 MENA license with Roots provides eligibility for up to $4 million in upfront fees and potential initial development milestones.
- Minor point. Forward-looking: it has not happened yet and may not happen.OCU400 received provisional approval and priority designation in The Bahamas; GARM will coordinate patient care.
11 minor points
- Minor pointOCU400 manufacturing qualification batches completed to support its biologics license application and commercial launch supply.
- Minor point. Forward-looking: it has not happened yet and may not happen.OCU400 Phase 3 trial involving 140 patients has data expected in Q1 2027, followed by a planned license application.
- Minor point. Forward-looking: it has not happened yet and may not happen.OCU410ST pivotal trial involving 63 subjects has data anticipated in Q2 2027, followed by a planned license application.
- Minor pointOCU410 global Phase 3 ArMaDa3 trial began dosing its first patient.
- Minor pointQ3 revenue increased to $1.951 million from $1.752 million a year earlier.
- Minor pointQ3 derivative-liability fair-value change generated a $16.562 million gain, versus none a year earlier.
- Minor pointQ3 general and administrative expenses declined to $7.204 million from $8.228 million a year earlier.
- Minor pointQ3 interest income increased to $649,000 from $207,000 a year earlier.
- Minor pointNine-month revenue increased to $4.973 million from $4.606 million a year earlier.
- Minor pointNine-month net loss narrowed to $47.653 million, or $0.14 per share, from $50.140 million, or $0.17.
- Minor pointLong-term debt, net, declined to $1.743 million from $27.542 million at December 31, 2025.
Negative
- Major pointCurrent convertible notes totaled $83.117 million at September 30, 2026, versus none at December 31, 2025.
- Moderate pointCurrent liabilities totaled $118.901 million against $91.427 million in current assets at September 30, 2026.
- Moderate pointQ3 weighted-average shares increased to 339,214,302 from 304,003,247 a year earlier.
- Moderate pointNine-month research and development expenses increased to $34.445 million from $29.081 million a year earlier.
- Moderate pointNine-month operating loss widened to $52.035 million from $45.921 million a year earlier.
8 minor points
- Minor pointOCU400 Bahamas access remains subject to final LARTA approval; potential patient enrollment is as early as year-end.
- Minor pointStockholders’ deficit widened to $17.681 million from $12.166 million at December 31, 2025.
- Minor pointQ3 research and development expenses increased to $12.500 million from $11.149 million a year earlier.
- Minor pointQ3 operating loss widened to $17.753 million from $17.625 million a year earlier.
- Minor pointQ3 interest expense increased to $3.090 million from $1.314 million a year earlier.
- Minor pointNine-month general and administrative expenses increased to $22.563 million from $21.446 million a year earlier.
- Minor pointNine-month interest expense increased to $8.886 million from $3.856 million a year earlier.
- Minor pointNine-month debt-extinguishment loss totaled $2.383 million, versus none a year earlier.
News Explained
As of
Key Figures
- MENA license upfront and initial milestones
- Up to $4 million
- Combined upfront license fee and potential initial development milestone payments
- MENA sales milestones
- Up to $255 million
- Potential sales milestones under the exclusive OCU400 license
- MENA net-sales royalty
- 22%
- Royalty on net sales under the exclusive OCU400 license
- Cash and investments
- $84.6 million
- As of September 30, 2026; company stated expected runway into 2028
- ArMaDa3 trial size
- 240 subjects
- Global Phase 3 OCU410 trial; patients randomized 2:1
- OCU400 liMeliGhT topline data
- 140 patients; first quarter of 2027
- Phase 3 trial; planned BLA submission to follow
- OCU410ST topline data
- 63 subjects; second quarter of 2027
- Phase 2/3 pivotal confirmatory trial
- Net loss per common share
- $(0.01) vs. $(0.07)
- Three months ended September 30, 2026 vs. 2025
Previous Earnings Reports
-
FDA cleared OCU410's ArMaDa3 Phase 3 trial after Phase 2 results; the update also reported financing and runway.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biologics license application regulatory
process performance qualification technical
subretinal injection medical
geographic atrophy medical
convertible notes financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Today at 8:30 a.m. ET
- Received Provisional Approval and Priority Designation for OCU400 in The Bahamas
- Executed agreement with local partner Global Alliance for Regenerative Medicine (GARM) to coordinate and manage patient care
- Progressing site readiness in preparation to accept patients
- Advancing toward full approval and potential patient enrollment as early as year-end
- Executed an exclusive OCU400 license agreement for the Middle East and North Africa (MENA) with Roots Pharmaceutical
- Initiated dosing in Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA)
- Cash, cash equivalents, restricted cash, and short-term investments of
$84.6 million as of September 30, 2026; with expected runway into 2028
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2026 financial results along with a general business update.
“With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen. “As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.”
Ocugen continues to advance its three late-stage modifier gene therapy programs toward key clinical and regulatory milestones, with OCU400 expected to be the first Phase 3 study to read out in the first quarter of 2027. The Company remains focused on execution across its pivotal programs while preparing for potential regulatory submissions and broader patient access opportunities.
Clinical Program Updates
OCU400 (RP)
- Granted Provisional Approval and Priority Designation from the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas; agreement with local partner, GARM, to manage process; site readiness progressing; LARTA final approval and potential patient enrollment as early as year-end
- Completed an exclusive OCU400 license for MENA with Roots Pharmaceutical. Ocugen is eligible for up to
$4 million in combined upfront license fee and potential initial development milestone payments, up to$255 million of potential sales milestones, and a22% royalty on net sales, and will manufacture commercial supply. It is Ocugen’s second regional OCU400 license agreement, following Kwangdong Pharmaceutical in South Korea - Top-line data from the 140-patient Phase 3 liMeliGhT trial are expected in the first quarter of 2027, followed by a planned Biologics License Application (BLA) submission; completed Process Performance Qualification (PPQ) batches to support the BLA and commercial launch supply
OCU410ST (Stargardt disease)
- Topline data from the Phase 2/3 pivotal confirmatory trial (N=63 subjects) are anticipated in the second quarter of 2027, with a planned BLA submission to follow
OCU410 (GA)
- Announced the first patient dosed in ArMaDa3, a 240-subject global Phase 3 trial randomizing patients 2:1 to a single subretinal injection of OCU410 or untreated control across the U.S., Canada, and Europe; the primary endpoint is GA lesion growth over 12 months
- Presented 12-month Phase 2 ArMaDa2 results at three scientific conferences, including two podium presentations at AAO 2026
Corporate Updates
- Named Jolanda Crombach General Manager of its newly established European affiliate in Amsterdam to support the OCU410 Phase 3 development program, upcoming marketing authorization submissions, and potential commercialization in Europe. Ms. Crombach most recently served as Managing Director and Board Member of Moderna Netherlands and previously held leadership roles at MSD (Merck) and Pfizer
Third Quarter 2026 Financial Results
- The Company’s cash, cash equivalents, restricted cash, and short-term investments totaled
$84.6 million as of September 30, 2026, which is expected to extend the runway into 2028 - The Company had 339.3 million shares of common stock outstanding as of September 30, 2026
- Total operating expenses for the three months ended September 30, 2026, were
$19.7 million and included research and development expenses of$12.5 million and general and administrative expenses of$7.2 million , compared to total operating expenses for the three months ended September 30, 2025, of$19.4 million that included research and development expenses of$11.1 million and general and administrative expenses of$8.2 million - Ocugen reported a
$(0.01) net loss per common share for the three months ended September 30, 2026, compared to a$(0.07) net loss per common share for the three months ended September 30, 2025
Conference Call and Webcast Details
Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s senior management team will host the call, which will be open to all listeners. There will also be a question-and-answer session following the prepared remarks.
Attendees are invited to participate on the call using the following details:
Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 6835403
Webcast: https://edge.media-server.com/mmc/p/w8rytgud (also available on the investor section of the Ocugen website)
A replay of the call and archived webcast will be available on the Ocugen investor site.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow the Company on LinkedIn and X.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of enrollment and data readouts, the ability to initiate new clinical programs, Ocugen’s financial condition and expected cash runway into 2028, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, statements regarding the ability to obtain the full LARTA approval in The Bahamas, and statements regarding the anticipated benefits to Ocugen of the definitive license agreement and supply agreement with Roots Pharmaceutical, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that receipt of Provisional LARTA Approval and Priority Designation may not lead to faster regulatory review and full approval, that the license agreement and supply agreement with Roots Pharmaceutical Company will not lead to the current anticipated benefits to Ocugen, that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contacts
Investors:
Candice Masse, astr partners
candice.masse@astrpartners.com
Media:
Chris Clark, Ocugen
chris.clark@ocugen.com
(Tables to follow)
| OCUGEN, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) (Unaudited) | ||||||
| Sep 30, 2026 | Dec 31, 2025 | |||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 24,632 | $ | 18,571 | ||
| Short-term investments | 59,625 | - | ||||
| Prepaid expenses and other current assets | 7,170 | 5,769 | ||||
| Total current assets | 91,427 | 24,340 | ||||
| Property and equipment, net | 12,711 | 14,392 | ||||
| Restricted cash | 321 | 316 | ||||
| Other assets | 3,602 | 4,468 | ||||
| Total assets | $ | 108,061 | $ | 43,516 | ||
| Liabilities and stockholders' equity | ||||||
| Current liabilities | ||||||
| Accounts payable | $ | 5,074 | $ | 6,202 | ||
| Accrued expenses and other current liabilities | 12,683 | 14,733 | ||||
| Operating lease obligations | 846 | 858 | ||||
| Convertible notes | 83,117 | - | ||||
| Derivative liability | 17,146 | - | ||||
| Current portion of long-term debt | 35 | 1,250 | ||||
| Total current liabilities | 118,901 | 23,043 | ||||
| Non-current liabilities | ||||||
| Operating lease obligations, less current portion | 2,821 | 3,494 | ||||
| Long term debt, net | 1,743 | 27,542 | ||||
| Other non-current liabilities | 2,277 | 1,603 | ||||
| Total non-current liabilities | 6,841 | 32,639 | ||||
| Total liabilities | $ | 125,742 | $ | 55,682 | ||
| Stockholders' equity (deficit) | ||||||
| Common stock | 3,392 | 3,125 | ||||
| Treasury stock | (48) | (48) | ||||
| Additional paid-in capital | 434,548 | 392,763 | ||||
| Accumulated other comprehensive income | 146 | 61 | ||||
| Accumulated deficit | (455,719) | (408,067) | ||||
| Total stockholders' equity (deficit) | (17,681) | (12,166) | ||||
| Total liabilities and stockholders' equity | $ | 108,061 | $ | 43,516 | ||
| OCUGEN, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share amounts) (Unaudited) | |||||||||||||||
| Three months ended Sep 30, | Nine months ended Sep 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Collaborative arrangement revenue | $ | 1,951 | $ | 1,752 | $ | 4,973 | $ | 4,606 | |||||||
| Total revenue | 1,951 | 1,752 | 4,973 | 4,606 | |||||||||||
| Operating expenses | |||||||||||||||
| Research and development | 12,500 | 11,149 | 34,445 | 29,081 | |||||||||||
| General and administrative | 7,204 | 8,228 | 22,563 | 21,446 | |||||||||||
| Total operating expenses | $ | 19,704 | $ | 19,377 | $ | 57,008 | $ | 50,527 | |||||||
| Loss from operations | (17,753) | (17,625) | (52,035) | (45,921) | |||||||||||
| Interest income | 649 | 207 | 1,174 | 778 | |||||||||||
| Interest expense | (3,090) | (1,314) | (8,886) | (3,856) | |||||||||||
| Loss on extinguishment of debt | - | - | (2,383) | - | |||||||||||
| Change in fair value of derivative liability | 16,562 | - | 14,671 | - | |||||||||||
| Other (expense) income, net | 34 | (1,319) | (194) | (1,141) | |||||||||||
| Total other (expense) income | $ | 14,155 | $ | (2,426) | $ | 4,382 | $ | (4,219) | |||||||
| Net loss | $ | (3,598) | $ | (20,051) | $ | (47,653) | $ | (50,140) | |||||||
| Other comprehensive income (loss) | |||||||||||||||
| Foreign currency translation adjustment | 26 | 46 | 179 | 10 | |||||||||||
| Unrealized loss on short-term investments | (93) | - | (93) | - | |||||||||||
| Comprehensive loss | $ | (3,665) | $ | (20,005) | $ | (47,567) | $ | (50,130) | |||||||
| Net loss attributable to common shareholders — basic and diluted | (3,598) | (20,051) | (47,653) | (50,140) | |||||||||||
| Weighted shares used in calculating net loss per common share — basic and diluted | 339,214,302 | 304,003,247 | 335,188,753 | 296,066,314 | |||||||||||
| Net loss per share attributable to common shareholders — basic and diluted | $ | (0.01) | $ | (0.07) | $ | (0.14) | $ | (0.17) | |||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Ocugen’s third-quarter 2026 financial results?
Ocugen reported revenue of $1.951 million and a net loss of $3.598 million, or $0.01 per share. In the comparable 2025 quarter, revenue was $1.752 million and net loss was $20.051 million, or $0.07 per share.
When does Ocugen expect OCU400 and OCU410ST trial results?
Ocugen expects OCU400 Phase 3 liMeliGhT results in the first quarter of 2027 and anticipates OCU410ST pivotal confirmatory results in the second quarter of 2027. Biologics license applications are planned after the respective readouts.
How is Ocugen’s OCU410 Phase 3 ArMaDa3 trial designed?
ArMaDa3 is a 240-subject global trial assigning patients 2:1 to a single injection beneath the retina of OCU410 or an untreated control group. The trial spans the United States, Canada and Europe. Its primary endpoint is geographic atrophy lesion growth over 12 months.
Who will manufacture OCU400 for Ocugen’s MENA licensing agreement?
Ocugen will manufacture commercial supply under the exclusive OCU400 license agreement with Roots Pharmaceutical for the Middle East and North Africa.